Industry Overview - The artificial intelligence (AI) in pathology market is projected to reach $1.15 billion by 2033, growing at a CAGR of 27.18% from 2025 to 2033, driven by demand for precision medicine, increasing chronic disease prevalence, and technological advancements in diagnostic tools [1] Company Developments - Tempus AI acquired Paige, a leading AI-driven digital pathology company, enhancing its capabilities with a proprietary dataset of nearly 7 million clinically annotated, digitized pathology slides [2] - Following the acquisition, Tempus launched Paige Predict, a suite of advanced digital pathology applications that analyze hematoxylin and eosin (H&E) whole-slide images to support informed testing decisions, predicting 123 biomarkers and oncogenic molecular pathways across 16 cancer types [3][7] - Labcorp entered a collaboration with Roche in 2025 to implement FDA-cleared VENTANA DP 600 and DP 200 slide scanners, enhancing efficiency and supporting AI integration in its anatomic pathology services [4] - Labcorp's Biopharma Laboratory Services added digital pathology capabilities and agreed to acquire select technical assets of Incyte Diagnostics' anatomic pathology business [5] - Quest Diagnostics introduced a new testing panel for amyloid brain pathology in symptomatic patients and acquired PathAI Diagnostics to accelerate AI adoption in digital pathology [6]